Fig. 1 · Structure
Documents & Downloads
BPU17
EMT Inhibitor, PHB1 Activator
BPU17 is an EMT inhibitor and PHB1 activator that disrupts the interaction between PHB1 and PHB2, leading to mild mitochondrial dysfunction. This impairment inhibits SRF/CArG-box-dependent transcription, consequently suppressing the epithelial-mesenchymal transition (EMT) in retinal pigment epithelial cells (RPEs). BPU17 demonstrates antifibrotic properties in vivo and holds potential for research aimed at developing therapeutic strategies for anti-neovascular age-related macular degeneration (nAMD).
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2198977-68-1 |
| Applications | EMT Inhibitor, PHB1 Activator |
| Formula | C12H13ClN2O2 |
| Molecular Weight | 252.70 |
| SMILES | ClC1=CC=C(NC(NC(C2CCC2)=O)=O)C=C1 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.